AbbVie (ABBV)
(Delayed Data from NYSE)
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
AbbVie (ABBV) Tops Q2 Earnings and Revenues, View Up
by Zacks Equity Research
AbbVie's (ABBV) second-quarter 2018 earnings surpassed estimates with revenues marginally beating the same. Topline boosted by strong sales growth of Humira, Imbruvica and Mavyret.
5 Must-See Earnings Charts to End the Week
by Tracey Ryniec
There's more earnings excitement still to come as many investor favorites report.
AbbVie Secures FDA Approval for Endometriosis Drug Elagolix
by Zacks Equity Research
AbbVie (ABBV) gains an FDA approval for its late-stage pipeline candidate, Orilissa, for the treatment of moderate to severe pain associated with endometriosis in women.
Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive second-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.
Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?
by Zacks Equity Research
Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret, might lead the company to an earnings beat in the second quarter.
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) is likely to witness solid growth in the core Pharmaceutical segment in Q4 results. However, lackluster performance in the Cordis unit is likely to mar prospects.
Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?
by Zacks Equity Research
Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.
Healthcare ETFs to Buy on Solid Q2 Earnings Expectations
by Sweta Killa
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Bristol-Myers (BMY) is scheduled to report second-quarter earnings on Jul 26.
Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?
by Zacks Equity Research
Gilead (GILD) is likely to beat expectations in the second quarter propelled by the momentum in the HIV franchise.
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
by Zacks Equity Research
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance
Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.
J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.
Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
AbbVie's Imbruvica Fails in Phase III Blood Cancer Study
by Zacks Equity Research
AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.
J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2.
The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie
Celebrate Trump's 2nd Year in Office With These 5 Winners
by Tirthankar Chakraborty
There's always a 67% chance that the U.S. stock market will scale north during the second year of presidential terms.
3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July
by Madhu Goel
We take a look at the three large cap pharma stocks that might be best bargains for the month of July.
Bristol-Myers' Sprycel Gets EC Approval for Label Expansion
by Zacks Equity Research
Bristol-Myers (BMY) receives EC approval for the label expansion of Sprycel for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in patients aged one to 18 years.
Here's Why AbbVie Stock is Good for Your Portfolio's Health
by Zacks Equity Research
Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.
Is Pfizer's Price Hike an Effect of Drug Policy on Sector?
by Zacks Equity Research
Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.